Navigation Links
Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Date:10/1/2013

CORK, Ireland, Oct. 1, 2013 /PRNewswire/ -- Janssen R&D Ireland (Janssen) announced that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease at the upcoming Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which will take place November 1 to 5 in Washington, D.C.

"Simeprevir's clinical profile has been characterized through a robust clinical development program including more than 3,700 patients," said Gaston Picchio, Disease Area Leader Hepatitis, Janssen. "The study results that will be presented at the AASLD Annual Meeting support the potential utility of simeprevir in a number of different hepatitis C patient populations."

Simeprevir was approved in Japan in September 2013 for the treatment of genotype 1 hepatitis C. In the U.S., the New Drug Application (NDA) filed by Janssen for simeprevir administered once daily in combination with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients was granted Priority Review designation by the Food and Drug Administration (FDA) in May. Simeprevir is also being studied in several interferon-free regimens using selected combinations of direct-acting antiviral agents with different mechanisms of action.

The data to be presented at the 2013 AASLD Annual Meeting include:

Poster Presentations: HCV Therapeutics: New Agents, Poster Hall, November 3, 8:00 a.m. - 5:30 p.m. (EST)

  • Simeprevir (TMC435) with peg-interferon alpha-2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: Efficacy and safety in patient sub-populations in the PROMIS
    '/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
2. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
3. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
4. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
5. Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
6. U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
7. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
8. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
9. Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy
10. Bulgaria Launches Development of National Hepatitis Plan
11. Major Breakthrough in Hepatitis C Vaccine Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)...  When Ryan Rendino first felt the ... neck, he figured it was a muscle ... from weight lifting. But the ... A series of doctor appointments followed ... Michel Kliot, MD , a Northwestern ...
(Date:5/21/2015)... 2015  CryoLife, Inc. (NYSE: CRY ), a ... cardiac and vascular surgery, announced today that its Board ... the second quarter 2015 of $0.03 per share of ... per share will be paid on June 19, 2015 ... 12, 2015.  The ex-dividend date for the quarterly dividend ...
(Date:5/21/2015)... Mai 2015 Dipexium Pharmaceuticals, ... Unternehmen für Arzneimittel im fortgeschrittenen Entwicklungsstadium, ... Vermarktung von Locilex® (Pexiganan-Creme 0,8 %) und ... wissenschaftliche Posterpräsentation an, welche das innovative ... OneStep-1 und OneStep-2, in der Locilex® ...
Breaking Medicine Technology:Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4CryoLife Announces Quarterly Cash Dividend for the Second Quarter 2015 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 4Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 5Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 6Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 7
... a global leader in minimally invasive cryotherapy treatments for ... establishing its new Global Headquarters in Minneapolis, MN. ... in Arden Hills during the fourth quarter of 2009. ... functions, the company will also locate its global marketing, ...
... alternative therapy for Parkinson,s , NEW YORK, Sept. 30 ... Center have reached a milestone in the development of potential ... of current therapy. , The team, which received an MJFF ... LEAPS (Linked Efforts to Accelerate Parkinson,s Solutions) initiative, ...
Cached Medicine Technology:Galil Medical Announces Establishment of Global Headquarters in Minneapolis, MN 2Michael J. Fox Foundation-Funded Team Pursuing Glutamate-Based Treatment for Parkinson's Disease Hits Major Milestone 2
(Date:5/24/2015)... Indiana Fiber Network, LLC (IFN), the ... of America, Inc. (MTA) has selected IFN as a ... IFN Enterprise Sales Manager, fiber route diversity and network ... transport provides MTA with the diverse fiber transport from ... Internet and voice carriers located at Henry Street in ...
(Date:5/23/2015)... On May 13, Nithyananda Yoga Foundation organized ... power learned through meditation and initiation at Special Holistic ... , Yogamaatha, a nine-year-old girl from North Carolina, stunned ... attending the 2015 Business Advocacy Summit at Capitol Hill ... , In a demonstration that lasted three hours, Yogamaatha ...
(Date:5/23/2015)... (PRWEB) May 23, 2015 Manufacturers are now ... Performance Factor (HSPF) of 8.2. Experts in the field agree ... benefit consumers. , The HSPF score is what miles per ... more efficient the unit. Although the minimum HSPF score has ... heaters with an HSPF score north of 12. Indeed, the ...
(Date:5/22/2015)... Calif. (PRWEB) May 22, 2015 ... technology, communication and capacity are intersecting to create ... across society, the opening speaker at WesternU's 34th ... California Lieut. Gov. Gavin Newsom, a former San ... the keynote speaker at the graduation ceremony for ...
(Date:5/22/2015)... New York (PRWEB) May 22, 2015 ... ) filed on behalf of individuals who allegedly ... to its use continue to move forward in ... According to a Pretrial Order dated May 4, ... preservation of documents and electronically stored information. Among ...
Breaking Medicine News(10 mins):Health News:Indiana Fiber Network, LLC Enables Midwest Telecom of America with Fiber Route Diversity 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3Health News:Parker & Sons Welcomes the Department of Energy’s Water Heater Regulation 2Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 3Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 4
... finds no connection between the two , , MONDAY, Jan. ... of evidence that rejects the idea that immunizations boost ... incidences of the disorder dropped after makers of most ... products. , Researchers found that autism rates in California ...
... prescriptions for children and adults , , MONDAY, Jan. 7 ... thoughts and behaviors in young people who take antidepressants ... research suggests. , The U.S. Food and Drug Administration ... selective serotonin reuptake inhibitors (SSRIs) might increase the risk ...
... for Emageon presentation, BIRMINGHAM, Ala., Jan. 7 ... in enterprise medical information technology,systems for hospitals, healthcare ... Chairman, CEO and President, will present at the,26th ... January 7-10, 2008,at the Westin St. Francis Hotel ...
... PARK, Calif., Jan. 7 ForSight Labs, LLC announced,today ... VISION3,Inc. with a Series A financing of $6 million, ... the medical technology arena: Morgenthaler,Ventures, Split Rock Partners and ... a significant round of funding to,develop our next innovative ...
... Va., Jan. 7 Specialty Blades, Inc. and ... completed its,acquisition of Popper and Sons, Inc. The ... tubing medical device manufacturing company,makes the combined company ... for the medical device industry. Specialty Blades,originally announced ...
... kept exam dates, study finds , , MONDAY, Jan. 7 ... time in the short-term, people who do so tend not ... Time saved with an Internet purchase may translate into ... that people purchasing lenses from wholesale clubs or optical chains ...
Cached Medicine News:Health News:Study Casts Doubt on Vaccine-Autism Link 2Health News:Study Casts Doubt on Vaccine-Autism Link 3Health News:Youth Suicide Warnings Are Slowing Antidepressant Sales 2Health News:ForSight Labs, LLC Announces Formation of Its Third Company, ForSight VISION3, Inc. and Closing of $6 Million in Series A Funding 2Health News:ForSight Labs, LLC Announces Formation of Its Third Company, ForSight VISION3, Inc. and Closing of $6 Million in Series A Funding 3Health News:Eye Care Lacking in Many Who Buy Contact Lenses Online 2
Micro instruments designed to provide maximum grasping, resecting capability, and excellent maneuverability for easy access to tight, small joints (wrist, elbow, and ankle).,Features pinless hinge d...
... The Stryker Cross-Screw System offers ... secure method for ACL reconstruction ... Stryker Cross-Screw System provides the ... The implant comes in Titanium ...
The Stryker Bioabsorbable Wedge Interference Screw is made of Poly-L Lactic Acid (PLLA). The patented wedge design makes it perfect for cruciate reconstruction and is indicated for BTB and soft tissu...
The Stryker Shoulder Instrumentation Set is ideal for open and arthroscopic shoulder procedures. The kit includes all the necessary tools for bone and tissue preparation as well as suture management ...
Medicine Products: